Custom Search


Wednesday 01 December 1999

Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.

By: Verschraegen CF, Levenback C, Vincent M, Wolf J, Bevers M, Loyer E, Kudelka AP, Kavanagh JJ.

Ann N Y Acad Sci 2000;922:349-51

No abstract available

Use of this site is subject to the following terms of use